Pet GLP-1— what's real,
what's coming, what to do now.
The independent tracker for veterinary GLP-1 drugs. Okava's MEOW-1 cat trial reads out summer 2026. We're watching every signal so your overweight cat or dog has a plan when the science lands.
From the team behind GLP-1 Picks — the human-side telehealth tracker. The same diligence, applied to pets.
No FDA-approved GLP-1 exists for pets yet. We'll tell you the day that changes.
Cats
The Okava MEOW-1 trial puts cats first. Here's what owners need to know.
Is There an Ozempic for Cats?
Short answer: not yet — but cats are the first animals being studied. Two separate feline GLP-1 trials are running right now. Here's what's real.
GLP-1 for Cats — The Drug Class, the Trials, the Timeline
Two active clinical trials are testing pet-specific GLP-1 receptor agonists in overweight cats. Here's what GLP-1 actually is, why it works, and when the first feline drug realistically lands.
Cat Obesity — The Vet-Backed Guide
Feline obesity has reached crisis levels. 61% of US cats are now overweight or obese. Causes, health risks, what's coming, what to do today.
Overweight Cat — What to Do
Your cat is in the majority — 61% of US cats are overweight. Here's the honest, vet-backed method. Cat GLP-1 drugs are coming, but you don't have to wait.
Dogs
No FDA-approved GLP-1 for dogs exists yet. Here's what works today.
Is There an Ozempic for Dogs?
Short answer: not yet — but the first GLP-1 trials in companion animals are running in cats right now. Here's the real status.
Dog Obesity — The Vet-Backed Guide
59% of US dogs are now overweight or obese. The 2019 University of Liverpool study showed it costs them up to 2.5 years of life. Here's what works.
Overweight Dog: What's Actually Going On
If your dog is overweight, you're in the majority — APOP's vet survey put US canine overweight/obesity at 59%. Here's the honest, vet-backed answer.
Why Your Labrador Is Always Hungry
It's not your fault, and it's not really your Lab's fault either. Cambridge researchers identified a gene deletion in roughly 25% of Labradors that genetically wires them to seek food constantly. Here's the science — and what actually works.
Dog Weight Loss: The Method That Works
The Association for Pet Obesity Prevention's most recent vet survey put the percentage of overweight or obese US dogs at 59%. Here's how to fix it without crash dieting or waiting for canine GLP-1.
Best Dog Food for Weight Loss
The top three vet-recommended weight management foods compared, with specs sourced directly from manufacturer guaranteed analysis.
Low Fat Dog Food: Complete Guide
For pancreatitis recovery, sensitive stomachs, and hyperlipidemia. Prescription and over-the-counter options compared.
The Pipeline
Trials, regulatory milestones, and the historical context behind every pet GLP-1 drug.
What Is MEOW-1?
MEOW-1 is the world's first clinical trial of a pet-specific GLP-1 weight loss drug. Run by Okava, in cats, with results due summer 2026.
MEOW-1 Results — Live Tracker
When Okava publishes the MEOW-1 cat GLP-1 trial readout this summer, we'll update this page with the full data within hours. Until then: here's what we're watching for.
OKV-119 — The Drug, The Implant, The Trial
OKV-119 is Okava Pharmaceuticals' investigational subcutaneous implant releasing exenatide — the active ingredient in Byetta and Bydureon — over approximately six months in cats.
Akston AKS-562c — Cornell Trial Readout Watch
Akston Biosciences' 11-week Cornell feline trial treatment phase completed approximately mid-February 2026. As of May 19, 2026 — ~14 weeks of post-treatment silence — no readout has been announced. New development: Akston filed S-1/A amendment #30 plus a Free Writing Prospectus in mid-May 2026, confirming the IPO roadshow is now actively underway. No AKS-562c clinical data appeared in the amendment. We're tracking the roadshow, the silence, and what comes next.
AKS-562c — Akston's Once-Weekly Cat GLP-1 Injection
AKS-562c is Akston Biosciences' investigational GLP-1 receptor agonist — a novel Fc-fusion protein delivered as a once-weekly subcutaneous injection in cats. Cornell trial readout expected Q2-Q3 2026.
LOY-002 — The Canine Longevity Drug Setting the FDA Template
Loyal Pharma's LOY-002 isn't a GLP-1, but it's the most advanced novel veterinary biologic moving through the FDA conditional approval pathway — the same framework Akston AKS-562c and Okava OKV-119 will use.
Pet GLP-1 Trial Tracker
Live tracker for the two GLP-1 weight management trials in companion animals — Okava's OKV-119 implant and Akston's AKS-562c injection.
Slentrol — The Dog Weight Loss Drug That Got Pulled
Slentrol was the first and only FDA-approved canine weight loss drug. Approved 2007, voluntarily discontinued in 2013. Here's the full story.
We'll tell you the day pet GLP-1 lands.
Okava MEOW-1 trial results drop summer 2026. Real FDA approval for canine GLP-1 likely 2028-2029. We're watching the signal so you don't have to.
Get Trial Alerts →